加注细胞疗法,阿斯利康10亿美元重金收购这家企业!

国际金融报
17 Mar

当地时间 3 月 17 日,阿斯利康连续发布4个公告,宣布两大交易。其中一个是宣布收购 EsoBiotec 以推进细胞治疗。另一个是宣布和Alteogen Inc. 已就ALT-B4达成独家许可协议,这是一种利用Hybrozyme平台技术的新型透明质酸酶,阿斯利康将使用ALT-B4开发和商业化多种肿瘤药物的皮下制剂。  根据阿斯利康官网公告,公司将以最高10亿美元的总价收购EsoBiotec的所有...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10